Evidence map›Paper›PMID 31272258›Full record

ArticleLeukemia & lymphoma2019

Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population.

Rajshekhar Chakraborty, Lisa Rybicki, Jacqulyn Tomer, Christy J Samaras, Beth M Faiman, Jason Valent, Navneet S Majhail

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis.Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rajshekhar ChakrabortyTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Lisa RybickiTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jacqulyn TomerTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Christy J SamarasTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Beth M FaimanTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jason ValentTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Navneet S MajhailTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Cleveland Clinic · US

Funding

Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
Improving Survivorship Care for Adolescents and Young Adults: a Mixed Methods Study of Alignment with the National Standards for Survivorship CareU01CA246659 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S · 2020 to 2025
$3.6M
NCI NIH HHS R01 CA215134NCI NIH HHS U01 CA246659
6 · The paper itself

Abstract

We performed an observational study on health-related quality of life (HRQoL) in patients with AL amyloidosis diagnosed between 2012 and 2017 at our institution. A total of 81 patients were included, with a median age of 64 years. The mean FACT-G (Functional Assessment of Cancer Therapy-General) total score at baseline (≤2 months from diagnosis) was 74 (±15), compared to a normative score of 80 (±18) in the general U.S. population. Significant HRQoL deficit was noted only in the functional well-being (FWB) domain of FACT-G. Using PROMIS-GH (Patient-Reported Outcomes Measurement Information System-Global Health) at baseline (

Indexed as

Global HealthPatient Reported Outcome MeasuresQuality of LifeAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansImmunoglobulin Light-chain AmyloidosisMaleMiddle AgedPrognosisRetrospective StudiesSurveys and QuestionnairesSurvival Ratehealth-related quality of lifeLight-chain amyloidosispatient-reported outcomes

Identifiers

PMID31272258
PMCPMC6928422
OpenAlexW2953951549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.